Biology and treatment of basal-like breast cancer

Bingchen Han, William Audeh, Yanli Jin, Sanjay P. Bagaria, Xiaojiang Cui

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Breast cancer is one of the most common cancers identified among women worldwide. It is a heterogeneous disease, with each sub-disease displaying unique clinical and histopathologic characteristics. Based on genomic analysis and gene expression profiling, breast cancer has been classified into several distinct subgroups. Estrogen receptor (ER)-positive breast cancers can be treated with antiestrogen drugs such as tamoxifen, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be treated with HER2-targeted drugs such as trastuzumab. Because of the low expression of ER and HER2, patients with basal-like breast cancer cannot benefit from these targeted therapies. Thus, to identify and validate pivotal theranostic biomarkers for basal-like breast cancer is of paramount importance. This chapter describes the molecular and histological features of basal-like breast cancer as well as the differences between basal-like breast cancer and the other breast cancer subtypes. It presents current progress in identifying the biomarkers for basal-like breast cancer. It concludes with a description of the current therapeutic strategies to treat basal-like breast cancer and argues that inhibition of basal-like tumor-associated signaling pathways, in conjunction with standard therapies, may enhance the treatment efficacy.

Original languageEnglish (US)
Title of host publicationCell and Molecular Biology of Breast Cancer
PublisherHumana Press Inc.
Number of pages19
ISBN (Electronic)9781627036344
ISBN (Print)1627036334, 9781627036337
StatePublished - Jun 1 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biology and treatment of basal-like breast cancer'. Together they form a unique fingerprint.

Cite this